References
- Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocrine Relat Cancer 2001;8:287–305.
- Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 2007;156:203–216.
- Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab 2007;92:2861–2865.
- Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365–374.
- Leung AK, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Phys 2004;70:543–550.
- Jackson J, Safranek S, Daugird A. Clinical inquiries. What is the recommended evaluation and treatment for elevated serum prolactin? J Fam Pract 2005;54:897–901.
- Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008;37:67–99.
- Nagel E, editor. Das Gesundheitswesen in Deutschland. Struktur, Leistungen, Weiterentwicklung. Köln: Deutscher Ärzte-Verlag; 2007.
- Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuroendocrinol Lett 2005;26:152–159.
- Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G. Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2006;2:200–210.
- Cibula D. Women's contraceptive practices and sexual behaviour in Europe. Eur J Contracept Reprod Health Care 2008;13:362–375.
- Bashour H, Hafez R, Abdulsalam A. Syrian women's perceptions and experiences of ultrasound screening in pregnancy: implications for antenatal policy. Reprod Health Matters 2005;13:147–154.
- Bronstein MD, Salgado LR, de Castro Musolino NR. Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 2002;5:99–107.
- Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331:904–909.
- Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinetics 2003;42:633–645.